A PYMNTS Company

US: Surescripts moves to dismiss FTC antitrust case

By  |  July 15, 2019

Surescripts has moved to dismiss the Federal Trade Commission’s (FTC) charge from earlier this year that it holds an illegal monopoly on the e-prescribing market.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    This past April, the FTC alleged that Surescripts “intentionally set out to keep e-prescription routing and eligibility customers on both sides of each market from using additional platforms (a practice known as multihoming) using anticompetitive exclusivity agreements, threats, and other exclusionary tactics.”

    FTC stated its suit aims to counter that outsized influence and competition in the marketplace and to provide “monetary redress to consumers.”

    FTC has stated its case against Surescripts was just part of its larger ongoing efforts to end anti-competitive practices that put consumers at a disadvantage and raise the cost of care.

    “Surescripts’ illegal contracts denied customers and, ultimately, patients, the benefits of competition – including lower prices, increased output, thriving innovation, higher quality, and more customer choice,” said FTC Bureau of Competition Director Bruce Hoffman in April. “Through this litigation, we hope to eliminate the anticompetitive conduct, open the relevant markets to competition, and redress the harm that Surescripts’s conduct has caused.”

    Full Content: Healthcarw It News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.